Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

This Small Biotech Will Profit From the Hep C Drug Race

By Brian Orelli, PhD and Max Macaluso - Mar 13, 2014 at 7:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Gilead and AbbVie are set to gain the most from developing new hepatitis C cocktails; Enanta Pharmaceuticals will benefit from AbbVie's sales.

Gilead Sciences ( GILD 1.20% ) and AbbVie ( ABBV 1.89% ) are in a race to get the first all-oral hepatitis C treatment for patients infected with genotype 1 hepatitis C virus. Gilead's cocktail is already submitted to the Food and Drug Administration, and AbbVie expects to submit its application in the second quarter.

Currently, patients have to take an injected medication called peginterferon, which causes annoying side effects that feel like the flu, so the all-oral cocktails will be a huge step forward, rewarding Gilead and AbbVie handsomely for their efforts.

There's a third player in this race that doesn't get as much attention: Enanta Pharmaceuticals ( ENTA -0.77% ), which helped develop one of the components of AbbVie's cocktail. The small biotech will benefit through double-digit royalties on ABT-450. Watch the video below for more information on Enanta's potential.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$69.75 (1.20%) $0.82
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$117.46 (1.89%) $2.18
Enanta Pharmaceuticals, Inc. Stock Quote
Enanta Pharmaceuticals, Inc.
ENTA
$87.60 (-0.77%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.